CVrg’s Heart Failure reports including comprehensive device coverage along with the subindications of chronic heart failure with reduced ejection fraction, chronic heart failure with preserved ejection fraction, acute heart failure, and the related disease of hypertrophic cardiomyopathy, provides comprehensive support through the life of your HF, DCM, and HCM assets.
Disease Area Analyst, Heart Failure
Matt received his Ph.D. in Cardiovascular Physiology from Colorado State University, where his research focused on the mechanisms of age-related impairments in skeletal muscle blood flow regulation and therapeutic strategies for improving vascular function with advancing age in humans. In addition to over 10 years of combined preclinical and clinical research experience, Matt brings to CVrg expertise in evaluating, synthesizing, and disseminating scientific/clinical evidence in academia and the medical device industry. He leverages this background to deliver valuable analyses and thoughtful insights to CVrg’s clients.
Martha Klovstad, Ph.D.
Therapy Area Director, Heart Failure
Martha received her doctorate in Molecular Biology from Princeton University and completed postdoctoral training at Stanford University. She is an experienced analyst with broad scientific and therapeutic expertise and strong analytical capabilities and leads CVrg’s heart failure team.
|CVrg Market Strategies™||
Heart Failure, 2020–2029 is a cutting-edge detailed market research report with unmatched scope, depth, and accuracy. This best-in-class resource provides a highly granular assessment of new product development, emerging trends, unmet needs, epidemiology, current treatment and market landscapes.
KOL comments, SWOTs, clinical trial tracking, estimations of launch dates and target patient populations are included for products ≥Ph 2 along with regional coverage of USA, EU5, and Japan. Fresh new data and analytical observations gained throughout the year in HF from CVrg Sentinel, Conference, Insights and Advisory research are also included.
CVrg continuously monitors how new scientific, clinical, regulatory and market developments are changing the commercial potential of HF assets. This monthly delivery informs clients about what is happening in the marketplace and how it might affect their products.
CVrg keeps abreast of cutting edge clinical data by attending cardio-metabolic congresses such as ACC, ESC and AHA. Our experts carefully analyze the new data presented and deliver incisive, presentation-style reports informing subscriber organizations about what’s new, what’s important, and why.
|CVrg KOL Insights™||
CVrg experts conduct primary research with KOLs in HF, using their critical eyes to evaluate emerging trends, pipeline products and implications for the field. Clients may review and add to our “omnibus” discussion guides and receive detailed reports and presentations focused on answering the most pressing issues they face today.
answers & new content
CVrg is uniquely positioned to deliver quick, thorough and reliable answers to non-proprietary questions in heart failure drug and device markets. We are immediately equipped with comprehensive data and put our best methodologies and efforts behind each inquiry so clients receive the most accurate insight possible within a given timeframe.